Takeda Collaborates with Skyhawk Therapeutics to Develop RNA Splicing Modifiers for Neurodegenerative Diseases
Shots:
- Skyhawk to receive upfront- milestones & royalties on sales and will discover & preclinically develop targeted therapies utilizing its SkySTAR technology. Takeda to get an exclusive WW license to develop & commercialize targeted therapies for multiple neurodegenerative diseases
- The focus of the agreement is to develop therapies directing central nervous system for improvement of targeted neurological disorders
- Skyhawk’s SkySTAR technology involves RNA splicing- correcting the RNA expression in small molecule for neurological diseases
Ref: PRNewswire | Image: Takeda
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com